Maia Biotechnology Inc MAIA:NYSE American

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
3.31UNCH (UNCH)
Volume
1,355,351
Close
3.31quote price arrow up+0.19 (+6.09%)
Volume
424,011
52 week range
0.82 - 3.59
Loading...
  • Open3.00
  • Day High3.43
  • Day Low3.00
  • Prev Close3.12
  • 52 Week High3.59
  • 52 Week High Date04/30/24
  • 52 Week Low0.82
  • 52 Week Low Date12/11/23

Key Stats

  • Market Cap72.281M
  • Shares Out21.84M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change182.91

KEY STATS

  • Open3.00
  • Day High3.43
  • Day Low3.00
  • Prev Close3.12
  • 52 Week High3.59
  • 52 Week High Date04/30/24
  • 52 Week Low0.82
  • 52 Week Low Date12/11/23
  • Market Cap72.281M
  • Shares Out21.84M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change182.91

RATIOS/PROFITABILITY

  • EPS (TTM)-1.57
  • P/E (TTM)-2.11
  • Fwd P/E (NTM)-2.09
  • EBITDA (TTM)-19.947M
  • ROE (TTM)-440.12%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Maia Biotechnology Inc

 

Profile

MORE
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer...
Vlad Vitoc M.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Jeffrey Himmelreich
Principal Financial and Accounting Officer, Head of Finance
Address
444 West Lake Street
Suite 1700, Suite 1700
Chicago, IL
60606
United States